Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2006-04-25
2006-04-25
Azpuru, Carlos A. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S428000
Reexamination Certificate
active
07033605
ABSTRACT:
Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
REFERENCES:
patent: 3416530 (1968-12-01), Ness
patent: 3432592 (1969-03-01), Speiser
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3921632 (1975-11-01), Bardani
patent: 4008864 (1977-02-01), Torphammar et al.
patent: 4063064 (1977-12-01), Saunders et al.
patent: 4088864 (1978-05-01), Theeuwes et al.
patent: 4144317 (1979-03-01), Higuchi et al.
patent: 4200098 (1980-04-01), Ayer et al.
patent: 4201210 (1980-05-01), Hughes et al.
patent: 4285987 (1981-08-01), Ayer et al.
patent: 4300557 (1981-11-01), Refojo et al.
patent: 4304765 (1981-12-01), Shell et al.
patent: 4451254 (1984-05-01), Dinius et al.
patent: 4668506 (1987-05-01), Bawa
patent: 4801460 (1989-01-01), Goertz et al.
patent: 4806337 (1989-02-01), Snipes et al.
patent: 4853224 (1989-08-01), Wong
patent: 4863457 (1989-09-01), Lee
patent: 4959217 (1990-09-01), Sanders et al.
patent: 4997652 (1991-03-01), Wong
patent: 5004601 (1991-04-01), Snipes
patent: 5004614 (1991-04-01), Staniforth
patent: 5006342 (1991-04-01), Cleary et al.
patent: 5082655 (1992-01-01), Snipes et al.
patent: 5164188 (1992-11-01), Wong
patent: 5378475 (1995-01-01), Smith et al.
patent: 5443505 (1995-08-01), Wong et al.
patent: 5476511 (1995-12-01), Gwon et al.
patent: 5501856 (1996-03-01), Ohtori et al.
patent: 5660847 (1997-08-01), Magruder et al.
patent: 5660851 (1997-08-01), Domb
patent: 5693335 (1997-12-01), Xia et al.
patent: 5755785 (1998-05-01), Rowsey et al.
patent: 5766242 (1998-06-01), Wong et al.
patent: 5824072 (1998-10-01), Wong
patent: 5824074 (1998-10-01), Koch
patent: 5869079 (1999-02-01), Wong et al.
patent: 5882682 (1999-03-01), Rork et al.
patent: 5941250 (1999-08-01), Aramant et al.
patent: 5962027 (1999-10-01), Hughes
patent: 5972369 (1999-10-01), Roorda et al.
patent: 6045791 (2000-04-01), Liu
patent: 6217895 (2001-04-01), Guo et al.
patent: 6331313 (2001-12-01), Wong et al.
patent: 6548078 (2003-04-01), Guo et al.
patent: 6699493 (2004-03-01), Wong
patent: 6726918 (2004-04-01), Wong et al.
patent: 0430539 (1990-11-01), None
patent: 0430539 (1991-06-01), None
patent: 0488401 (1992-06-01), None
patent: 0654256 (1995-05-01), None
patent: 94/18956 (1994-09-01), None
patent: 95/13765 (1995-05-01), None
patent: 98/22130 (1998-05-01), None
patent: WO 99/11244 (1998-08-01), None
patent: 99/11244 (1999-03-01), None
patent: 00/37056 (2000-06-01), None
patent: 00/62760 (2000-10-01), None
patent: 01/30323 (2001-05-01), None
patent: 02/02076 (2002-01-01), None
Enyedi, Laura et al.,An Intravitreal Device Providing Sustained Release of Cyclosporine and Dexamethasone, Current Eye Research (1995) pp. 549-557.
Hainsworth, Dean P. et al.,Sustained Release Intravitreal Dexamethasone, Journal of Ocular Pharmacology and Therapeutics, (1996) vol. 12, No. 1, pp. 57-63.
Morita Y., et al.,Intraviteous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid)implants, Biol. Pharm. Bull., Feb. 1998; 21(2): 188-90.
Nakamura O., et al.,Inhibition of neovascularization and tumor growth by dexamethasone, No To Shinkei, Jan. 1992;44(1):37-41.
Dohlman C. et al.,Treatment of corneal edema with a buried implant, Tr. Am. Acad. Opth. & Otol., Mar.-Apr. 1966, pp. 267-280.
Algvere, et al. (1997). “Transplantation of RPE in Age-Related Macular Degeneration: Observations in Disciform Lesions and Dry RPE Atrophy,”Graefes Arch Clin Exp Opthalmol.235(3):149-158.
Apel, A. et al. (1996). “A Subconjunctival Degradable Implant for Cyclosporine Delivery in Corneal Transplant Therapy,”Current Eye Research14(8):659-667.
Barnas, U. et al. (1997). “Parameters Associated with Chronic Renal Transplant Failure,”Nephrol. Dial. Transplant.1 Suppl: 8-85.
Bennett, W.M. and Barry, J.M. (1979). “Failure of Dexamethasone to Provide Adequate Chronic Immunosuppression for Renal Transplantation,”Transplantation27(3):218-219.
Bigar and Hebort (1992), “Corneal Transplantation,”Curr. Opin. Ophthalmol.3(4):473-481.
Bloch-Michel, E. (1992). “Opening Address: Intermediate Uveitis”In Intermediate Uveitis, Dev. Ophthalmol.W.R.F. Böke et al. eds., Karger: Basel vol. 3, pp. 1-2.
Bodor, N. et al. (1992). “A Comparison of Intraocular Pressure Elevating Activity of Loteprednol Etabonate and Dexamethasone in Rabbits,”Current Eye Research11:525-530.
Böke, W.R.F. et al., (1992). “Clinical Picture of Intermediate Unveitis”In Intermediate Uveitis. Dev. Ophthalmol.W.R.F. Böke et al., eds. Basel: Karger, vol. 23, pp. 20-27.
Budavari, S. et al., eds. (1996). The Merck Index, 12thEdition. Merck and Co., Rahway, N.J. (Table of Contents only, 2 pages).
Bundgaard, H. and Mø, J. (1989). “Prodrugs of Peptides IV: Bioreversible Derivatization of the Pyroglutamyl Group by N-Acylation and N-Aminomethylation to Effect Protection against Pyroglutamyl Aminopeptidease,” J. Pharm. Sci. 78:122-126.
Burdon and McDonnell (1995). “A Survey of Corneal Graft Practice in the United Kingdom,”Eye9(Pt 6 Su):6-12.
Chacko et al. (2000). “Survival and Differentiation of Cultured Retinal Progenitors Transplanted in the Subretinal Space of the Rat.”Biochem Biophys Res Commun.268(3):842-846.
Cheng, C.K. et al. (1995). “Intravitreal Sustained-Release Dexamethasone Device in the Treatment of Experimental Uveitis,”Invest. Ophthalmol. Vis. Sci.36(2):442-453.
Cuff. G. and Raouf. F. (1998). “A Preliminary Evaluation of Injection Molding as a Technology to Product Tablets,”Pharmaceutical Technologypp. 96-106.
Davis, P.A. et al. (1992). “Intraocular Implant for Controlled 5-Fluorouracil Release,”Proc. Int. Symp. Controlled Release Bioact. Mater.19:339-340.
Encyclopedia of Polymer Science and Technologyvol. 3. Interscience Publishers, Inc., New York (Table of Contents only, p. v).
Enzmann et al. (1998). “Immunological Problems of Tranplantation into the Subretinal Space.”Acta Anat.(Basel). 162(2-3):178-183.
Gennaro, A.R. ed. (1995). Remington:The Science and Practice of Pharmacy, 19thEdition. Mack Publishing Company, Easton, PA (Table of Contents only, pp. xv-xvi).
Gilman, A.G. et al., eds. (1990)Goodman and Gilman 's: The Pharmacological Basis of Terapeutics.8thEdition, Pergamon Press: New York, (Table of Contents only, pp. xi-xvi).
Goodman and Gilman,The Pharmacological Basis of Terapeutics.9thEdition, McGraw-Hill, New York, (Table of Contents only, pp. v-xii).
Gould, L. et al. (1994). “Fifty:fifty Poly (DL Glycolic Acid-Lactic Acid) Copolymer as a Drug Delivery System for 5-Fluorouracil: A Histopathological Evaluation,”Canadian Journal of Ophthalmology29(4):168-171.
Guan, D. et al. “The Therapeutic Window of Cyclosporine in Chinese Recipients of Renal Transplantation,”Transplant Proc.27(1):850-851.
Hari, P. and Srivastava, R.N. (1998). “Pulse Corticosteroid Therapy with Methylprednisolone or Dexamethasone,”Indian J. Pediatr.65(4):557-560.
Heller, J. (1987). “Biodegradable Polymers in Controlled Drug Delivery”In CRC Critical Reviews in Therapeutic Drug Carrier Systems.CRC Press, Boca Raton: FL, vol. 1. issue 1, pp. 39-90.
Hirano, T. (1994). “Clinical Significance of Glucocorticoid Pharmacodynamics Assessed by Antilymphocyte Action in Kidney Transplantion,”Transplantation57(9):1341-1348.
Kher, V. et al. (1992). “Low-Dose Dexamethasone-an Alternative Therapy of Acture Renal Allograft Rejection,”Transplant Proc.24(5):1725.
Kochinke, F. and Wong, V.G. (1996). “Boiodegradable Drug Delivery System for Uveitis Treatment,”Investigative Ophthalmology&Visual Science37(3). (1 page).
Kochinke, F. and Wong, V.G. (1996). “Boiodegradable Drug Delivery System for Uveitis Treatm
Allergan Inc.
Azpuru Carlos A.
Donovan Stephen
LandOfFree
Methods for reducing or preventing transplant rejection in... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for reducing or preventing transplant rejection in..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for reducing or preventing transplant rejection in... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3531276